Cue Biopharma Inc V.CUE

Primary Symbol: CUE

Healthcare Biotechnology

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.

NDAQ:CUE - Post by User

Cue Biopharma Inc > what is your time frame

<< Previous

Bullboard Posts

Next >>

Comment by Strodon Jan 17, 2011 8:10am

273 Views

Post# 17982341

RE: RE: RE: what is your time frame

Most of my position was taken in the last deal, but some from before and added a bit recently. I thought the results may have pushed us higher but they are not spectacular at this point so thats the way it goes. Not sure any position has panned out exactly as I thought so just par for the course. Patience is king.

<< Previous

Bullboard Posts

Next >>

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide